



Supplementary Figure S1. Flow cytometry analysis of ovarian cancer ascites cells, related to Figure 1. **A**, Gating strategy for analyzing CD11b⁺CD64⁺ ovarian cancer ascites cells, related to Figure 1B. **B**, Fluorescence intensity histograms showing Clever-1 expression in CD11b⁺CD64⁺ cells of a representative ovarian cancer patient, related to Figure 1C. **C – E**, Clever-1 expression was measured from permeabilized CD11b⁺CD64⁺ ascites cells before and after treating ascites cells for 48h with bexmarilimab or IgG4 (n = 8 patients). Violin plots of total Clever-1 expression (**C**), fluorescence intensity histograms of a representative patient (**D**), and percentage of Clever-1⁺ CD11b⁺CD64⁺ cells (**E**) are shown. Horizontal lines in violin plots mark median and quartiles. RM one-way ANOVA followed by Tukey's test; ns, not significant. BEX, bexmarilimab; IgG4, isotype control for bexmarilimab.